Tesla Down 8% on Q3 Production Disappointment
Tesla shares are trading 8.42% lower at $242.58 after the production figures published yesterday by the company disappointed analysts and investors.
Tesla shares are trading 8.42% lower at $242.58 after the production figures published yesterday by the company disappointed analysts and investors.
Credit Suisse stock is trading 7.11% lower at 3.64 Swiss Francs (CHF) in Zurich Swiss Exchange as investors worry about the financial health of the bank. Credit Suisse officials spend the weekend on phone calls
2022 has been a tough year for investors around the globe as all indices slipped into a bear market. The aggressive rate hikes by the Federal Reserve throughout the year, the Russia-Ukraine war, high inflation
Nike NKE drops over 10% in premarket trading after the company reported the first fiscal quarter that disappointed investors due to rising inventories and low margins
USDINR is trading unchanged after the central bank of India (RBI) six-member Monetary Policy Committee delivered the third 50 basis point interest-rate hike in its attempt to battle inflation in the country while targeting to protect the economy
Apple stock was under pressure for the second consecutive trading session as the sell-off in stocks accelerated across the board. S&P 500 is 2.16% lower at 3,639, Nasdaq is 2.84%
Porsche a subsidiary of Volkswagen will start trading free on the Frankfurt Stock Exchange. The first day of trading is September 29 making it one of the biggest IPOs
DocuSign announced today a restructuring plan which includes the layoff of 9% of its total workforce. The restructuring plan target is to improve the profitability, growth and operating margin.
Here are some of the top broker’s price targets for Netflix (NFLX) shares and the dates of the target price released. The highest target for Netflix shares is $325 while the lowest target price is at $170.
Eisai (ESALY) and Biogen Inc. (BIIB) announced that their experimental Alzheimer’s drug slowed the progression of the disease in the latest Phase 3 trial of 1795 patients.
